Target intelligence / Profile preview

Platelet (resting state) (None)

Target
None
Molecular classification
Other (cellular state, not a molecule or family)
01

Overview

Platelets are small, anucleate cell fragments circulating in blood, derived from megakaryocytes. In their resting (unactivated) state, they circulate inertly, maintained by continuous inhibition from endothelial factors such as nitric oxide and prostacyclin. Resting platelets have a distinctive discoid morphology, maintain low intracellular calcium, and possess surface molecules such as glycoprotein Ib-IX-V and GPVI in an unengaged conformation. On blood vessel injury, platelets rapidly transition to the activated state, facilitating adhesion, secretion, and aggregation to form a platelet plug and initiate coagulation. The resting state is crucial for preventing unwanted thrombosis under physiologic conditions. Unactivated platelets do not execute procoagulant functions but have the molecular machinery to respond quickly when activated.

Other names
Resting plateletsquiescent plateletsnon-activated plateletsinactive platelets
02

Mechanism of action

Not applicable. Drugs target receptors or signaling molecules involved in platelet activation, e.g., P2Y12 antagonists inhibit ADP-induced platelet activation and aggregation.

03

Biological functions

Hemostasis (potential once activated)Maintenance of vascular integrity (as surveillance cells)Reservoir for signaling molecules and chemokines (upon activation)
04

Disease associations

Not direct; roles become relevant upon activation in: Cardiovascular diseaseThrombosis (activated platelets)Bleeding disorders (deficiency or dysfunction)
05

Safety considerations

Not applicable for unactivated platelets. However, excessive inhibition of platelet activation with anti-platelet drugs can lead to bleeding risk or bruising
06

Interacting drugs

None specific to “unactivated platelets”, but platelet-activation inhibitors (e.g., clopidogrel, aspirin) prevent activation of platelets
07

Biomarkers

Platelet number (count)mean platelet volume (MPV—higher in younger/resting platelets)surface markers (CD41/CD42b)—typically used to profile the cell, not as efficacy markers for resting state specifically

Beyond the preview

Go deeper on Platelet (resting state) (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Platelet (resting state) (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call